Galleri is a cancer detection test by Grail. The test is not yet approved by the FDA (Grail)

Hims adds cancer detection test to Labs product

Its lab analysis product will be a central part of the company’s upcoming Super Bowl ad.

2/4/26 9:00AM

Hims & Hers will add Galleri, a cancer detection test made by Grail, to its offerings as it works to expand its Labs product.

Hims said Wednesday that it would add the blood test, which says it detects signals for over 50 types of cancer before symptoms appear, to its portfolio. It comes at a $250 discount to the Galleri list price, which is $949, but it’s available only to Labs subscribers.

Hims rose by as much as 5% early trading following the announcement after several days of declines.

Hims launched its lab analysis product, which is a central part of its upcoming Super Bowl commercial, in November. The advertisement unveiled last week alluded to a cancer detection product. Grail announced in October that it raised $325 million from several investors, including Hims. The company did not give specifics of its business relationship with Grail or how the investment plays into it.

Hims’ labs product initially marketed two tiers: a base plan that costs $199 per year or an advanced plan for $499. It now offers a single plan at $349 a year. It’s one of several product expansions the company has announced as it pivots focus away from weight-loss treatments.

Screenshot 2026-02-02 at 3.39.18 PM — A screen shot of Hims & Hers’ upcoming Super Bowl commercial posted on January 29, 2026 (Sherwood News)

Grail has sold roughly 185,000 Galleri tests as of the end of 2025, according to a recent presentation the company gave at the JPMorgan Healthcare Conference in San Francisco. The Galleri tests brought in between $138 million and $139 million in revenue last year, up from $109 million in 2024.

Grail announced Thursday that it filed for Food and Drug Administration approval of its Galleri test. The test has been available commercially since 2021, but approval from the FDA could position it to be covered by major insurers.

The test has been available through partners like Quest Diagnostics and Function Health, a lab analysis startup offering a similar product to Hims, which announced it would offer Galleri tests in December.

Correction: An earlier version of this story provided outdated Hims Labs' pricing tiers.

Max Knoblauch

23h

Spotify expands its anti-AI verified badges to podcasts

Spotify introduced verified badges for musician profiles in late April.

Spotify Hosts a "Now Playing" Creator Day at its Los Angeles Campus

Tom Jones5/19/26

Demis Hassabis, Google DeepMind’s CEO and founder, was also an early Anthropic investor

A chess prodigy and an actual a knight of the realm in the UK, it’s perhaps no surprise that Demis Hassabis has made some strategic moves about his exposure to AI upside. According to people familiar with the matter, the influential AI architect became an angel investor in Anthropic, currently behind many of the leading AI models, per Arena AI leaderboards.

The Nobel Prize winner’s position in the Claude creator was previously undisclosed and, per the Financial Times, highlights Hassabis’ “growing influence across the AI industry.”

Google, which bought DeepMind, the company that Hassabis cofounded and heads to this day, for a reported ~$400 million in 2014, is also a key Anthropic investor. The tech giant reportedly plans to invest up to $40 billion in the AI company as part of the mutually beneficial relationship the pair have forged, with reports that Anthropic has committed to spending $200 billion in the other direction on Google’s cloud services over the next five years.

I’m playing all sides, so I always come out on top

In addition to his financial support for Anthropic, Hassabis has also invested in a range of AI startups launched by colleagues, such as Inflection AI, a company set up by DeepMind cofounder Mustafa Suleyman (who is now CEO of Microsoft AI), as well as efforts from other collaborators, like David Silver’s Ineffable Intelligence.

Hassabis also emerged as a recurring figure on the fringes of the recent Elon Musk v. Sam Altman trial, cropping up repeatedly in testimonies and court documents and appearing to live, as The Verge put it, “rent-free” in Musk’s head.

Founded in 2021, Anthropic has recently raised funding at a reported $900 billion valuation, sending it soaring ahead of competitor OpenAI.

Google DeepMind’s Demis Hassabis emerges as early Anthropic investor

The Nobel Prize winner’s position in the Claude creator was previously undisclosed and, per the Financial Times, highlights Hassabis’ “growing influence across the AI industry.”

I’m playing all sides, so I always come out on top

Founded in 2021, Anthropic has recently raised funding at a reported $900 billion valuation, sending it soaring ahead of competitor OpenAI.

Max Knoblauch5/18/26

Jury rules against Musk in lawsuit against OpenAI and Altman

Jurors in Tesla CEO Elon Musk’s lawsuit against Sam Altman, Greg Brockman, and OpenAI found the defendants not liable on all claims on Monday.

In a unanimous verdict reached after less than two hours of deliberation, the Oakland jury found that Musk had waited too long to bring his case forward, exceeding the statute of limitations.

Musk had alleged that OpenAI abandoned its founding mission as a nonprofit dedicated to developing AI for humanity and instead became a profit-driven company closely tied to Microsoft.

The verdict caps off a three-week blockbuster tech trial that could have seen Altman and Brockman removed from OpenAI leadership.

Jury tosses Elon Musk’s lawsuit against OpenAI and Sam Altman

Musk had alleged that OpenAI abandoned its founding mission as a nonprofit dedicated to developing AI for humanity and instead became a profit-driven company closely tied to Microsoft.

The verdict caps off a three-week blockbuster tech trial that could have seen Altman and Brockman removed from OpenAI leadership.

Millie Giles

WRIST BUMP

5/18/26

Swatch’s collaboration with Audemars Piguet could help bring hype back to its bottom line

The rival watchmakers have teamed up on a buzzy new collection that’s sparking a global consumer frenzy.